uniQure N.V. Ordinary Shares vs TAL Education Group American Depositary Shares — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while TAL Education Group American Depositary Shares trades at $12.44 (market cap $7.01B). The key difference: TAL Education Group American Depositary Shares is far larger — about 4.7× uniQure N.V. Ordinary Shares's market cap, and TAL Education Group American Depositary Shares is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and TAL Education Group American Depositary Shares for 3 Days on average.
| QURE | TAL | |
|---|---|---|
Market Cap | $1.48B | $7.01B |
Volume | 2,488,780 | 3,223,678 |
Sector | Health | Consumer Staples |
52-Week High | $70.59 | $12.91 |
52-Week Low | $9.03 | $8.95 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $728.62M | $4.54B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TAL Education Group trades at $12.64, down 0.63% with strong bullish technical signals from moving averages. The company demonstrates impressive fundamental strength with 28.43% net income margin and 23.72% ROE, supported by three consecutive earnings beats. Revenue growth accelerated from $2.25B in 2025 to $3.2B in 2026, while profitability surged from $85M to $907M net income. Analyst consensus shows 42.86% buy ratings with price targets suggesting 27.63% upside potential.
TAL presents a compelling investment case with strong earnings momentum and attractive valuation at 7.92 P/E. However, investors face risks from China's regulatory environment and the company's negative cash flow position of -$465.75M in 2025. The technical setup supports near-term upside with key resistance at $13 and support at $12, while institutional sentiment remains positive despite cash flow concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →TAL Education Group provides smart learning solutions in China. Its offerings combine teaching content, technology, and learning services through various online and offline formats.
Read more on TAL →